2025 Q4 -tulosraportti
27 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 107 | - | - | ||
| 3 | - | - | ||
| 3 724 | - | - | ||
| 302 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
·2.3.Norne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.
·5.3.Yes, this is dead meat in my portfolio. Low turnover, impossible to get rid of. It will be a wait. And agree with Norne, this grows too slowly.·6 t sittenDNE is a pure trading company. They sell methadone in pre-dosed units. I know their products well from the medicine cabinet of an addiction institution. Strange that industry knowledge from a nurse should be relevant, but it was when I realized how good Buvidal ( Camurus) was, and how big it was going to become. Dne is a somewhat boring pharmacy product. They have a solid market position in a market that is not large or interesting enough for them to get competition. I don't remember them having other products in connection with the presentation at the acquisition. According to a statement from Andreassen a long time ago, the vision was to become an Orkla for pharmaceuticals. DNE fits well there. If one gathers enough such "soup and pizza producers" under them, there can be volume. Then the company becomes interesting. So the question is how fast to grow?
·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
27 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?
- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
- ·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
- ·2.3.Norne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.·5.3.Yes, this is dead meat in my portfolio. Low turnover, impossible to get rid of. It will be a wait. And agree with Norne, this grows too slowly.·6 t sittenDNE is a pure trading company. They sell methadone in pre-dosed units. I know their products well from the medicine cabinet of an addiction institution. Strange that industry knowledge from a nurse should be relevant, but it was when I realized how good Buvidal ( Camurus) was, and how big it was going to become. Dne is a somewhat boring pharmacy product. They have a solid market position in a market that is not large or interesting enough for them to get competition. I don't remember them having other products in connection with the presentation at the acquisition. According to a statement from Andreassen a long time ago, the vision was to become an Orkla for pharmaceuticals. DNE fits well there. If one gathers enough such "soup and pizza producers" under them, there can be volume. Then the company becomes interesting. So the question is how fast to grow?
- ·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 107 | - | - | ||
| 3 | - | - | ||
| 3 724 | - | - | ||
| 302 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
27 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?
- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
- ·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
- ·2.3.Norne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.·5.3.Yes, this is dead meat in my portfolio. Low turnover, impossible to get rid of. It will be a wait. And agree with Norne, this grows too slowly.·6 t sittenDNE is a pure trading company. They sell methadone in pre-dosed units. I know their products well from the medicine cabinet of an addiction institution. Strange that industry knowledge from a nurse should be relevant, but it was when I realized how good Buvidal ( Camurus) was, and how big it was going to become. Dne is a somewhat boring pharmacy product. They have a solid market position in a market that is not large or interesting enough for them to get competition. I don't remember them having other products in connection with the presentation at the acquisition. According to a statement from Andreassen a long time ago, the vision was to become an Orkla for pharmaceuticals. DNE fits well there. If one gathers enough such "soup and pizza producers" under them, there can be volume. Then the company becomes interesting. So the question is how fast to grow?
- ·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 107 | - | - | ||
| 3 | - | - | ||
| 3 724 | - | - | ||
| 302 | - | - |
Välittäjätilasto
Dataa ei löytynyt